Novo Nordisk sees strong 2024 sales and profit growth
Shares of Denmark’s Novo Nordisk rose 3.5% to 613.30 kroner this morning, after the company reported better-than-expected net profit amid soaring demand for its Wegovy (semaglutide) obesity drugs, but forecast a slight slowdown in sales for 2025.
Medicine makes great money for Novo Nordisk – beats expectations
The most anticipated annual report in Denmark does not disappoint. Denmark’s largest company and leading pharmaceutical company Novo Nordisk is shoveling in money.The total profit is 101 billion DKK.
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely driven by strong demand in the United States.
Novo Nordisk: Q4 Earnings Snapshot
The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 83 cents per share.
Novo Nordisk Earnings Boost Stock in Ozempic Maker
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig
Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Novo Nordisk shares surge as Wegovy sales drive profit beat
Shares of Novo Nordisk climbed 4.5% on Wednesday after the Danish pharmaceutical giant reported a stronger-than-expected fourth-quarter net profit, driven by soaring demand for its obesity treatment,
Novo Nordisk shares surge as weight loss treatments boost profits
Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an investment foundation of Novo Nordisk, acquired three manufacturing sites in Catalent to expand its production capacity.
Hosted on MSN13m
Novo Nordisk Stock Jumps On Q4 Beat: Retail Brushes Off Slower Growth Outlook To Chase Obesity Drug Boom
NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...
Novo Nordisk files annual report with the SEC
Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and ...
manilatimes8h
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion.
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...
Novo Nordisk Foundation Will Not Fill Funding Gaps
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
4NVO : Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. If we consider the specifics of ...
Novo Nordisk Is Prepared for Trump’s Tariff Threat, CEO Says
Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...
Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year
In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving ...